Phase II trial of carboplatin, gemcitabine, and capecitabine in patients with carcinoma of unknown primary site

Cancer

Volumn 110, Issue 4, 2007, Pages 770-775

  Schneider, Bryan J ^a,d   El Rayes, Basil ^b   Muler, Jeffery H ^a   Philip, Philip A ^b   Kalemkerian, Gregory P ^a   Griffith, Kent A ^c   Zalupski, Mark M ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b KARMANOS CANCER INSTITUTE   (United States)

^c UNIVERSITY OF MICHIGAN COMPREHENSIVE CANCER CENTER   (United States)

^d UNIVERSITY OF MICHIGAN   (United States)

Author keywords

Capecitabine; Carcinoma of unknown primary; Chemotherapy; Experimental therapeutics; Gemcitabine

Indexed keywords

CA 19-9 ANTIGEN; CAPECITABINE; CARBOPLATIN; CARCINOEMBRYONIC ANTIGEN; GEMCITABINE;

ADENOCARCINOMA; ADULT; AGED; ANEMIA; AREA UNDER THE CURVE; ARTICLE; CARCINOMA; CARCINOMA OF UNKNOWN PRIMARY; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; DEEP VEIN THROMBOSIS; DIARRHEA; DRUG EFFICACY; EXPERIMENTAL THERAPY; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FEVER; HAND FOOT SYNDROME; HUMAN; LEUKOPENIA; LIVER METASTASIS; LIVER TOXICITY; LUNG EMBOLISM; LYMPH NODE METASTASIS; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; PERITONEUM METASTASIS; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SEPSIS; SQUAMOUS CELL CARCINOMA; STATISTICAL ANALYSIS; STOMATITIS; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTOPENIA; UNDIFFERENTIATED CARCINOMA; VOMITING;

ABDOMINAL NEOPLASMS; ADULT; AGED; ANEMIA; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOEMBRYONIC ANTIGEN; DEOXYCYTIDINE; FEMALE; FLUOROURACIL; HUMANS; KAPLAN-MEIERS ESTIMATE; LEUKOPENIA; LIVER NEOPLASMS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASMS, UNKNOWN PRIMARY; NEUTROPENIA; TREATMENT OUTCOME;

EID: 34547871272     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.22857     Document Type: Article

References (24)

1. Jemal A, Siegel R, Ward E. Cancer Statistics, 2006. CA Cancer J Clin. 2006;56:106-130.
2. Shildt RA, Kennedy PS, Chen TT, Athens JW, O'Bryan RM, Balcerzak SP. Management of patients with metastatic adenocarcinoma of unknown origin: a Southwest Oncology Group study. Cancer Treat Rep. 1983;67:77-79.
3. Pavlidis N, Briasoulis E, Hainsworth J, Greco FA. Diagnostic and therapeutic management of cancer of an unknown primary. Eur J Cancer. 2003;39:1990-2005.
4. Mayordomo JI, Guerra JM, Guijarro C, et al. Neoplasms of unknown primary site: a clinicopathological study of autopsied patients. Tumori. 1993;79:321-324.
5. National Comprehensive Cancer Network Practice Guidelines in Oncology, v. 1.2005. Occult Primary. Available at: http://www.nccn.org/professionals/ physician_gls/PDF/occult.pdf (Accessed 12/16/2006).
6. Lenzi R, Hess KR, Abbruzzese MC, Raber MN, Ordonez NG, Abbruzzese JL. Poorly differentiated carcinoma and poorly differentiated adenocarcinoma of unknown origin: favorable subsets of patients with unknown-primary carcinoma? J Clin Oncol. 1997;15:2056-2066.
7. Abbruzzese JL, Abbruzzese MC, Hess KR, Raber MN, Lenzi R, Frost P. Unknown primary carcinoma: natural history and prognostic factors in 657 consecutive patients. J Clin Oncol. 1994;12:1272-1280.
8. van de Wouw AJ, Jansen RL, Griffioen AW, Hillen HF. Clinical and immunohistochemical analysis of patients with unknown primary tumour. A search for prognostic factors in UPT. Anticancer Research. 2004;24:297-301.
9. Alberts AS, Falkson G, Falkson HC, van der Merwe MP. Treatment and prognosis of metastatic carcinoma of unknown primary: analysis of 100 patients. Med Pediatr Oncol. 1989;17:188-192.
10. Greco FA, Burris HA 3rd, Litchy S, et al. Gemcitabine, carboplatin, and paclitaxel for patients with carcinoma of unknown primary site: a Minnie Pearl Cancer Research Network study. J Clin Oncol. 2002;20:1651-1656.
11. Hainsworth JD, Spigel DR, Raefsky EL, et al. Combination chemotherapy with gemcitabine and irinotecan in patients with previously treated carcinoma of an unknown primary site: a Minnie Pearl Cancer Research Network Phase II trial. Cancer. 2005;104:1992-1997.
12. Langer CJ, Calvert P, Ozols RF. Gemcitabine and carboplatin in combination: phase I and phase II studies. Semin Oncol. 1998;25(4Suppl 9):51-54.
13. Kaufman D, Raghavan D, Carducci M, et al. Phase II trial of gemcitabine plus cisplatin in patients with metastatic urothelial cancer. J Clin Oncol. 2000;18:1921-1927.
14. Madajewicz S, Hentschel P, Burns P, et al. Phase I chemotherapy study of biochemical modulation of folinic acid and fluorouracil by gemcitabine in patients with solid tumor malignancies. J Clin Oncol. 2000;18:3553-3557.
15. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92:205-216.
16. Simon R. Optimal two-stage designs for phase II clinical trials. Control Clin Trials. 1989;10:1-10.
17. Parker SL, Tong T, Bolden S, Wingo PA. Cancer statistics, 1996. CA Cancer J Clin. 1996;46:5-27.
18. El-Rayes BF, Shields AF, Zalupski M, et al. A phase II study of carboplatin and paclitaxel in adenocarcinoma of unknown primary. Am J Clin Oncol. 2005;28:152-156.
19. Briasoulis E, Kalofonos H, Bafaloukos D, et al. Carboplatin plus paclitaxel in unknown primary carcinoma: a phase II Hellenic Cooperative Oncology Group Study. J Clin Oncol. 2000;18:3101-3107.
20. Greco FA, Rodriguez GI, Shaffer DW, et al. Carcinoma of unknown primary site: sequential treatment with paclitaxel/carboplatin/etoposide and gemcitabine/irinotecan: a Minnie Pearl Cancer Research Network phase II trial. Oncologist. 2004;9:644-652.
21. Hainsworth JD, Erland JB, Kalman LA, Schreeder MT, Greco FA. Carcinoma of unknown primary site: treatment with 1-hour paclitaxel, carboplatin, and extended-schedule etoposide. J Clin Oncol. 1997;15:2385-2393.
22. Hainsworth JD, Johnson DH, Greco FA. Cisplatin-based combination chemotherapy in the treatment of poorly differentiated carcinoma and poorly differentiated adenocarcinoma of unknown primary site: results of a 12-year experience. J Clin Oncol. 1992;10:912-922.
23. Pasterz R, Savaraj N, Burgess M. Prognostic factors in metastatic carcinoma of unknown primary. J Clin Oncol. 1986;4:1652-1657.
24. Nystrom JS, Weiner JM, Heffelfinger-Juttner J, Irwin LE, Bateman JR, Wolf RM. Metastatic and histologic presentations of unknown primary cancer. Semin Oncol. 1977;4:53-58.